“Evaluation of Microbial Risk Factors in Relation to Clinical Effectiveness of Off-Label Bevacizumab Use for Retinal Disease Treatment: Research Article”, Pak Euro. J. Med & LS, vol. 9, no. 1, pp. 25–34, Mar. 2026, doi: 10.31580/pjmls.v9i1.3417.